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abstract: Objectives: The incidence of lung cancer in Oman has shown a gradual but definitive increase since 
2002. This study aimed to evaluate the demographic and epidemiological characteristics and survival outcomes 
of patients with non-small-cell lung cancer (NSCLC) at a university hospital in Oman. Methods: This study was 
conducted from January to June 2016. A retrospective analysis was performed of consecutive patients diagnosed 
with NSCLC presenting to the Sultan Qaboos University Hospital (SQUH) in Muscat, Oman, between March 
2000 and December 2015. Clinical features at presentation and prognostic and predictive markers were reviewed. 
Kaplan-Meir estimates were used to determine relapse-free survival, progression-free survival (PFS) and overall 
survival (OS). Results: A total of 104 patients presented to SQUH during the study period. The median age at 
diagnosis was 64 years. Overall, 62 patients (59.6%) had adenocarcinomas. Only 12 patients (11.5%) presented in 
the early stages (I or II) of the disease and the majority of patients had an Eastern Cooperative Oncology Group 
performance status of 1 (27.9%) or 2 (26.0%). The prevalence of epidermal growth factor receptor mutations was 
27.9%. The median PFS for patients with advanced disease (stages III or IV) was five months and the median OS for 
all patients was seven months. After five years, 50.0%, 60.0%, 10.0% and 8.0% of patients with disease stages I, II, III 
and IV, respectively, were alive. Conclusion: Patients with NSCLC in Oman were found to present at an advanced 
stage. However, patient outcomes were similar to those reported in the USA.
Keywords: Non-Small-Cell Lung Carcinomas; Adenocarcinomas; Epidermal Growth Factor Receptor; Patient 
Outcome Assessment; Survival Analysis; Oman.
امللخ�ص: الهدف: اأظهرت االإح�سائيات اأن االإ�سابة ب�رصطان الرئة يف عمان تواجه زيادة تدريجية م�سطردة منذ عام 2002. تهدف هذه 
الدرا�سة اإىل تقييم اخل�سائ�ص الدميوغرافية والوبائية و نتائج جناة املر�سى الذين يعانون من �رصطان الرئة ذو اخلاليا غري ال�سغرية يف 
م�ست�سفى اجلامعة يف �سلطنة عمان. الطريقة: اأجريت هذه الدرا�سة يف الفرتة من يناير اإىل يونيو 2016. مت اإجراء حتليل ا�ستعادي للمر�سى 
املتتابعني الذين مت ت�سخي�سهم ب�رصطان الرئة ذو اخلاليا غري ال�سغرية يف م�ست�سفى جامعة ال�سلطان قابو�ص مب�سقط، عمان، بني مار�ص 
2000 ودي�سمرب 2015. متت مراجعة اخل�سائ�ص ال�رصيرية ووقت الت�سخي�ص باالإ�سافة لتحليل عوامل االإنذار والتنبوؤ مب�ستقبل املر�ص. وقد 
ا�ستخدمت تقديرات كابالن-مري لتحديد البقاء على قيد احلياة بدون انتكا�سة، البقاء على قيد احلياة بدون تقدم املر�ص والبقاء على قيد 
احلياة الكلي. النتائج: متت مراجعة ما جمموعه 104 مري�سا يف م�ست�سفى اجلامعة خالل فرتة الدرا�سة. وكان متو�سط اأعمار املر�سى عند 
الت�سخي�ص 64 عاما. اإجماال، كان 62 مري�سا )%59.6( يعانون من �رصطان الرئة الغدي. 12 مري�سا فقط )%11.5( مت ت�سخي�ص حاالتهم يف 
املراحل املبكرة )I اأو II( من املر�ص وكان لدى غالبية املر�سى حالة االأداء ترتاوح بني 1 )%27.9( اأو 2 )%26.0( ح�سب موؤ�رص جمموعة 
التعاون ال�رصقية لالأورام. وكان معدل انت�سار الطفرات يف م�ستقبالت عامل منو الب�رصة %27.9. كان متو�سط البقاء على قيد احلياة بدون 
تقدم املر�ص لدى املر�سى من ذوي املراحل املتقدمة وقت الت�سخي�ص )املرحلة III و IV( خم�سة اأ�سهر. بينما كان متو�سط البقاء على قيد 
احلياة الكلي جلميع املر�سى �سبعة اأ�سهر. كما وجدنا اأن %50.0 من مر�سى املرحلة I و %60.0 من مر�سى املرحلة II، %10.0 من مر�سى 
املرحلة III و %8.0 من مر�سى املرحلة IV بقوا على قيد احلياة بعد مرور خم�سة �سنوات من تاريخ الت�سخي�ص. اخلال�صة: املر�سى الذين 
نتائج عالج  كانت  ذلك،  متقدمة. ومع  مراحل  ت�سخي�ص حاالتهم يف  يتم  ال�سغرية يف عمان  اخلاليا غري  ذو  الرئة  يعانون من �رصطان 
املر�سى مماثلة لتلك التي وجدت يف الواليات املتحدة االأمريكية.
على البقاء  حتليل  املر�سى؛  نتائج  تقييم  الب�رصة؛  منو  عامل  م�ستقبالت  غدي؛  �رصطان  ال�سغرية؛  غري  اخلاليا  ذو  الرئة  �رصطان  املفتاحية:   الكلمات 
قيد احلياة؛ عمان.
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Advances in Knowledge
- This study presents the clinical and pathological features, treatment details and median progression-free and overall survival of Omani 
patients with non-small-cell lung cancer (NSCLC). To the best of the authors’ knowledge, this study is the first to describe the trends and 
outcomes of patients with NSCLC in Oman.
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Lung cancer has recently been identified as the most frequently occurring cancer and leading cause of cancer-related deaths 
worldwide, with an age-standardised incidence and 
mortality rate among men alone of 33.8% and 29.2%, 
respectively.1 Globally, it remains the most common 
form of cancer in men, with high rates in Europe, 
the USA and Eastern Asia and lower rates in Africa.1 
Since 2002, the incidence of lung cancer in Oman 
has been steadily rising over time; according to the 
Ministry of Health, lung cancer was ranked as the 
sixth most common cancer among men in 2013 (6.2%) 
and was the second most frequent cause of hospital-
based cancer-related deaths (8.7%) following stomach 
cancer.2 However, there is as yet no information 
regarding prognostic markers, presenting features and 
treatment outcomes among Omani patients. 
Lung cancer is associated with tobacco smoking 
and the risk of developing the disease increases with 
smoking duration and the number of cigarettes 
smoked; hence, lung cancer is considered to be a 
preventable disease.3 In the USA, the prevalence of 
heavy smoking (i.e. >30 cigarettes/day) has declined 
considerably; in contrast, a survey from Oman has 
shown a steadily increasing trend in smoking from 
a crude incidence of 6.7% in 1995 to 7.0% in 2004.4–6 
In addition, the majority of smokers are male, with 
13.4% of men smoking versus 0.5% of women.6 
Alarmingly, waterpipe smoking has also become more 
popular in Oman recently, especially among younger 
individuals.7,8 
The current study aimed to describe the 
demographic characteristics, clinicopathological 
features, management details and outcomes of 
patients with non-small-cell lung cancer (NSCLC) 
presenting at the Sultan Qaboos University Hospital 
(SQUH), a tertiary university hospital in Muscat, 
Oman. The results were subsequently compared with 
those of previous research from the USA regarding 
lung cancer-related outcomes.9
Methods
This non-concurrent retrospective study was 
conducted from January to June 2016 and included 
consecutive patients diagnosed with NSCLC presenting 
to SQUH between March 2000 and December 2015. 
Clinical and demographic data were reviewed using 
the hospital’s information system, including age, 
gender, race, weight loss, smoking habits, Eastern 
Cooperative Oncology Group (ECOG) performance 
status and the presence of any concurrent illnesses. 
Prognostic and predictive markers were also analysed, 
including histological subtype, tumour grade, disease 
stage, sites of metastasis, epidermal growth factor 
receptor (EGFR) mutation status, treatment offered, 
survival and the occurrence of side-effects. Tissue 
samples were sent abroad to a reference laboratory 
for EGFR and echinoderm microtubule-associated 
protein-like 4 (EML4) anaplastic lymphoma kinase 
(ALK) genetic testing. Cancer stages were defined 
as per the International Staging Committee criteria 
of the International Association for the Study of 
Lung Cancer.10 The histology results of patients who 
were referred from other hospitals to SQUH after 
diagnosis were reviewed, although the majority of 
patients had been diagnosed at SQUH. All patients 
with incomplete electronic data and those who had 
received treatment and follow-up elsewhere (n = 7) 
or individuals diagnosed with small-cell lung cancer 
(n = 14) were excluded from the study.
Data were analysed using the Statistical Package 
for the Social Sciences (SPSS), Version 20.0 (IBM 
Corp., Armonk, New York, USA). Relapse-free survival 
(RFS) was calculated as the period of time between the 
date of diagnosis until the date of documented relapse, 
while progression-free survival (PFS) was deemed 
to constitute the period of time between the date of 
diagnosis until the date of progression of the disease. 
Overall survival (OS) was measured as the period of 
time from the date of diagnosis to the date of death 
or until the last known date of follow-up as of June 
2016. Kaplan-Meir estimates were used to determine 
RFS, PFS and OS and the log-rank test was used for 
the comparative analysis. The Cox regression model 
was used for the multivariate analysis and included 
all statistically significant variables indicated by the 
univariate analysis. A P value of ≤0.050 was considered 
statistically significant.
This study was approved by the Research & 
Ethics Committee of the College of Medicine & Health 
Sciences, Sultan Qaboos University (MREC #641).
- These findings may act as a reference regarding associated clinicopathological features for patients with NSCLC from Oman as well as 
other countries in the Gulf Cooperative Council region.
Application to Patient Care
- Patient outcomes and survival rates are vital to help decide upon appropriate treatment regimens for patients with malignant disorders. 
- The availability of these local data from Oman may serve as a benchmark regarding lung cancer survival rates and will help clinicians 
during the treatment decision-making process.
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Results
A total of 104 patients with NSCLC were included in 
the study. The median age at diagnosis was 64 years 
(range: 35–85 years old) and the male-to-female ratio 
was 3:1. Over half of the patients (65.4%) were active 
or ex-smokers; of these, most were male (91.2%), 
with only six of the female patients (27.3%) having a 
history of smoking. The median time to presentation 
was two months (range: 1–5 months). There were 
96 Omanis (92.3%) and only eight expatriates (7.7%). 
Most patients had an ECOG performance status of 1 
(27.9%) or 2 (26.0%), while 10.6%, 20.2% and 15.4% of 
patients had ECOG performance statuses of 0, 3 and 
4, respectively.
Almost half of the patients (48.1%) had a history 
of significant weight loss. Nearly one-third of the 
patients (35.6%) had more than one comorbidity, with 
hypertension (47.1%), diabetes (26.9%) and chronic 
obstructive lung disease (25.0%) being most common. 
A total of 62 patients (59.6%) had adenocarcinomas. 
Of these, 43 (69.4%) were assessed for activating 
mutations in exons 19 or 21 of the EGFR gene, of 
which 12 (27.9%) harboured mutations. Of the 14 
patients (13.5%) who underwent EML4-ALK gene 
testing, only one (7.1%) had an ALK rearrangement. 
The commonest site of metastasis was in the bone 
(19.2%). The clinical, demographic and pathological 
characteristics of the patients are presented in Table 1.
Only 12 patients (11.5%) presented with early-
stage disease, including one patient (8.3%) at stage 
I and 11 patients (91.7%) at stage II. Of the patients 
Table 1: Baseline clinical, demographic and pathological 
characteristics of patients with non-small-cell lung 
cancer presenting to the Sultan Qaboos University 












Carcinoid tumour 2 (1.9)





Opposite lung 15 (14.4)
Liver 7 (6.7)
Adrenal glands 7 (6.7)
Brain and bone 6 (5.8)
Brain 5 (4.8)
Pleural effusion 4 (3.8)
Liver and bone 1 (1.0)





















Moderately differentiated 30 (28.8)
Poorly differentiated 62 (59.6)
Undifferentiated 7 (6.7)
Unknown 1 (1.0)
SCC = squamous cell carcinoma; ASCC = adenosquamous cell 
carcinoma; T1 = ≤3 cm; T2 = 3–7 cm; T3 = >7 cm; T4 = tumour 
of any size invading the mediastinum, heart, great vessels, trachea, 
recurrent laryngeal nerve, oesophagus, vertebral body, carina or 
separate tumor in different ipsilateral lobe; N0 = absence of nodal 
involvement; N1 = metastasis to the ipsilateral hilar or peribronchial 
lymp nodes; N2 = metastasis to the ipsilateral mediastinal or carinal 
lymp nodes; N3 = metastasis to the contralateral hilar, mediastinal or 
supraclavicular lymp nodes; Nx = nodal involvement unknown.
*On radiology.
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who presented with early-stage NSCLC, 10 (83.3%) 
underwent surgical resection. Seven patients received 
adjuvant chemotherapy, one patient was deemed unfit 
for chemotherapy and received adjuvant radiation 
therapy instead and two patients opted not to receive 
adjuvant therapy and later died due to progressive 
cancer (including one patient with an adenocarcinoma 
and another with squamous cell carcinoma [SCC]). 
Local and distant relapse was documented in two 
patients each, while four patients had both local 
and distant relapses. A total of 92 patients (88.4%) 
presented with more advanced disease (stage III or 
IV) and were treated palliatively; of these, 30 patients 
(32.6%) did not receive chemotherapy because they 
either refused treatment or were deemed unfit due to 
their poor ECOG performance status. 
Patients who received first-line chemotherapy 
were treated with a median of four cycles (range: 1–6 
cycles). Only seven patients received tyrosine-kinase 
inhibitors (TKIs) during the first line of chemotherapy, 
including erlotinib (n = 5), a combination of erlotinib 
and chemotherapy (n = 1) and gefitinib (n = 1). All 
of these patients experienced disease progression 
requiring second-line chemotherapy, except for 
one patient who died while receiving erlotinib. 
A total of 62 patients (59.6%) were treated with 
platinum doublets as first-line therapy. The first-line 
treatment regimens prescribed are shown in Table 2. 
Maintenance chemotherapy after induction therapy 
was offered to 11 patients who received a median of 
14 maintenance cycles (range: 4–26 cycles) before 
progression. A median of three cycles of second-line 
chemotherapy was administered (range: 1–17 cycles). 
Docetaxel alone was administered to 10 patients in the 
second line, while five patients received pemetrexed 
or gemcitabine with platinum. The remaining patients 
were treated with other single agents or a combination 
of regimens. Of the 35 patients who received second-
line chemotherapy, 19 (54.3%) also received third-
line chemotherapy. Docetaxel and erlotinib were the 
most commonly used third-line agents (21.1% each). 
Five patients (4.8%) were treated with five lines of 
chemotherapy.
In total, 83 patients (79.8%) died secondary to 
disease progression and eight (7.7%) died of non-
disease-related causes. At the time of writing, five 
patients (4.8%) were alive and actively receiving 
treatment, three patients (2.9%) who had received 
adjuvant chemotherapy were in remission, one patient 
(1.0%) was alive on best supportive care and one 
patient (1.0%) was alive and diseased, but under active 
observation due to a bronchial carcinoid tumour. 
The status of the remaining three patients (2.9%) was 
unknown as they were lost to follow-up. According 
to gender, median PFS was 19.0 months in females 
versus 7.4 months in males and OS was 22.2 months 
in females versus 10.5 months in males. Median RFS 
among patients with early-stage disease (stage I or II) 
was 29 months (range: 1–74 months), while median 
PFS among patients with more advanced disease (stage 
III or IV) was five months (range: five days–97 months) 
Table 2: First-line treatment regimens among patients 
with non-small-cell lung cancer presenting at the Sultan 
Qaboos University Hospital, Muscat, Oman (N = 104)
Regimen n (%)
Adenocarcinoma 62 (59.6)
Pemetrexed and carboplatin 17 (16.3)
BSC and palliative XRT 16 (15.4)
Gemcitabine and carboplatin 9 (8.7)
Erlotinib 5 (4.8)
Vinorelbine and carboplatin/cisplatin 4 (3.8)
Paclitaxel and carboplatin 4 (3.8)
Pemetrexed 2 (1.9)
Gemcitabine, carboplatin and bevacizumab 1 (1.0)
Pemetrexed, carboplatin and bevacizumab 1 (1.0)
Gefitinib 1 (1.0)
Pemetrexed, carboplatin and erlotinib 1 (1.0)
5-FU and platinum 1 (1.0)
ASCC 2 (1.9)
Paclitaxel and carboplatin 2 (1.9)
SCC 29 (27.9)
Gemcitabine and carboplatin 12 (11.5)
BSC 10 (9.6)
Gemcitabine 2 (1.9)
Paclitaxel and carboplatin 2 (1.9)
Nab-paclitaxel and carboplatin 1 (1.0)
Docetaxel and carboplatin 1 (1.0)
Etoposide, carboplatin and XRT 1 (1.0)
Undifferentiated 7 (6.7)
BSC 3 (2.9)
Gemcitabine and carboplatin 2 (1.9)
Paclitaxel and carboplatin 2 (1.9)
Large-cell cancer 2 (1.9)
Gemcitabine and carboplatin 1 (1.0)
Pemetrexed and carboplatin 1 (1.0)
Carcinoid tumour 2 (1.9)
Surveillance 2 (1.9)
BSC = best supportive care; XRT = radiotherapy; 5-FU = 5-fluorouracil; 
ASCC = adenosquamous cell carcinoma; SCC = squamous cell carcinoma.
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Table 3: Univariate analysis of factors affecting recurrence-free survival, progression-free survival and overall survival 
among patients with non-small-cell lung cancer presenting to the Sultan Qaboos University Hospital, Muscat, Oman 
(N = 104)
Variable RFS/PFS OS
95% CI P value 95% CI P value
Gender (male versus female) 3.40–6.59 0.007 2.96–35.03 0.055
Age group (<60 versus ≥60-year-olds) 3.41–6.58 0.220 4.82–13.17 0.023
Curative surgery 23.16–48.83 <0.001 0.00–187.72 <0.001
Disease stage at diagnosis 2.89–5.10 0.001 3.46–6.53 0.001
Smoking history 3.59–6.40 0.019 2.87–27.12 0.003
ECOG performance status 4.15–11.84 0.001 18.527–21.47 <0.001
Weight loss 2.46–7.54 0.070 5.31–16.68 0.011
N0 nodal status 25.26–46.73 0.003 0.0–173.65 0.001
Site of metastasis 5.93–10.06 0.005 7.65–28.34 <0.001
Chemotherapy approach (adjuvant versus palliative) 25.26–46.73 0.003 7.98–16.01 <0.001
Number of chemotherapy cycles 5.76–10.24 0.043 7.98–16.01 0.005
Chemotherapy-associated side-effects 3.12–6.87 0.006 3.17–18.82 0.120 
Treatment response 6.76–9.24 <0.001 4.29–9.70 <0.001
Radiation treatment - - 4.45–7.54 0.050
PFS - - 5.37–12.63 0.001
RFS = recurrence-free survival; PFS = progression-free survival; OS = overall survival, CI = confidence interval; ECOG = Eastern Cooperative 
Oncology Group; N0 = absence of nodal involvement.
Figure 1: Median (A) progression-free survival for all patients and (B) recurrence-free or progression-free survival 
according to stage among patients with non-small-cell lung cancer presenting to the Sultan Qaboos University Hospital, 
Muscat, Oman (N = 104).
Figure 2: Median overall survival for (A) all patients and (B) according to stage among patients with non-small-cell lung 
cancer presenting to the Sultan Qaboos University Hospital, Muscat, Oman (N = 104).
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[Figure 1]. The median OS for all patients was seven 
months (range: 7 days–123 months). At two and 
five years, OS was 96.0% and 7.0%, respectively. At 
two years, OS was 50.0%, 70.0%, 22.0% and 17.0% 
for patients with disease stages I, II, III and IV, 
respectively. After five years, 50.0%, 60.0%, 10.0% and 
8.0% of patients with stages I, II, III and IV were still 
alive [Figure 2].
On univariate analysis, females had a significantly 
higher median PFS rate (19.0 versus 7.4 months; 
P = 0.003) in comparison to males, although OS was 
not significantly different (19.0 versus 6.0 months; 
P = 0.055). Moreover, curative surgical resection, 
an early-stage diagnosis, never smoking, ECOG 
performance status, the absence of nodal involvement, 
the site of metastasis, chemotherapy approach, the 
number of cycles of chemotherapy administered, the 
presence of chemotherapy-associated side-effects and 
treatment response to first-line chemotherapy were 
also significantly associated with PFS (P <0.050 each). 
In addition, a younger age, curative surgical resection, 
an early-stage diagnosis, never smoking, ECOG 
performance status, weight loss, the absence of nodal 
involvement, the site of metastasis, chemotherapy 
approach, the number of chemotherapy cycles, 
receiving radiation therapy, treatment response to first-
line chemotherapy and PFS were significant factors 
affecting increased OS (P <0.050 each) [Table 3]. 
However, none of these factors were found to be 
statistically significant during the multivariate Cox 
regression analysis.
Discussion
In Oman, lung cancer is a major cause of cancer-
related deaths, warranting patient, physician and 
specialist awareness.2 While fewer patients are 
diagnosed with lung cancer in Oman as compared to 
neighbouring countries like the United Arab Emirates 
and Saudi Arabia, the age-standardised ratio for lung 
cancer is higher in Oman at 6.7 for males and 2.1 for 
females.2 Nevertheless, the incidence of lung cancer 
in Oman is lower than in other nearby countries like 
Egypt, Kuwait and Jordan.11,12 The mean age of the 
patient population in the current study (64 years) was 
consistent with that reported in previously published 
research (59.2 years).13 Moreover, age was significantly 
associated with poorer survival in the current study; 
while age is reportedly not prognostic for survival, it 
is known to be a poor prognostic factor for toxicity 
to chemotherapy.14
In the present study, NSCLC was more frequent 
among men; the lower incidence among Omani 
women may perhaps reflect the cultural taboo of 
tobacco smoking in females. Women also showed 
superior median PFS and OS compared to men; this 
correlates favourably with Western findings reported 
by Wisnivesky et al.15 A Norwegian study similarly 
reported that men with adenocarcinomas had a 
24% higher risk of death than women.16 However, 
environmental exposure, genetic predisposition, 
hormonal factors and viral infections may all play 
a role in lung cancer among women and never 
smokers, both of whom have a higher prevalence of 
adenocarcinomas.3,17 Zang et al. found that the odds 
ratio for adenocarcinomas was higher among females 
due to their greater susceptibility to carcinogens, 
regardless of level of exposure to tobacco smoke.18 
Adenocarcinoma subtypes are usually related to 
subpleural scars.19 While the incidence of SCC 
has decreased over the past few decades, that of 
adenocarcinomas has increased in both genders 
due to the introduction of filter vents that facilitate 
easier and deeper inhalation of tobacco-specific 
carcinogens.3 This was reflected in the current study 
in which a higher incidence of adenocarcinomas 
was observed in comparison to SCC. Additionally, 
according to the univariate analysis, never smokers 
in the present study had a significantly better PFS 
rate. Furthermore, the vast majority of smokers were 
male. Various carcinogens and cell signal pathways 
have been proposed to contribute to lung oncogenesis 
among never smokers.4 
Loss of body weight at presentation was associated 
with poorer survival in the present study, with almost 
half of the study sample losing >5% of their baseline 
weight; in addition, decreased ECOG performance 
status was associated with poor outcomes. Yang et al. 
also found that weight loss was associated with 
poorer survival.20 In a study of various chemotherapy 
regimens for patients with advanced NSCLC, 
Schiller et al. indicated that the absolute benefit of 
chemotherapy for one year and median OS varied 
inversely with poor ECOG performance status.21 
Multiple concurrent illnesses were noted in the current 
study which is understandable considering the fact 
that most of the patients were quite elderly. However, 
the frequency of these variables was too low to predict 
survival. The severity or burden of comorbidity has 
been reported to have a clear relationship with poor 
survival in lung cancer; for example, the Charlson 
Comorbidity Index is associated with increasing 
toxicity to chemotherapy.22,23 Ethnicity has also been 
found to have an impact on survival; a recent article 
indicated that African Americans had poorer survival 
prospects even though Caucasians had a higher risk of 
developing lung cancer.24 Most patients in the current 
study were Omani, with eight patients originating 
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from either Africa, Pakistan, the Philippines, India 
or Europe; unfortunately, due to the low number of 
expatriates, it was not possible to correlate race or 
ethnicity with survival.
The majority of patients in the current study were 
treated with platinum doublets. Bevacizumab could 
not be administered to many of the patients due to the 
presence of absolute or relative contraindications.25 
At SQUH, anticancer therapy is customised based 
on the histological subtype of NSCLC; pemetrexed 
and platinum doublets with or without bevacizumab 
are usually prescribed for adenocarcinomas, while 
platinum and gemcitabine or nab-paclitaxel are 
prescribed for SCC and TKIs for patients with 
adenocarcinomas also harbouring EGFR mutations. 
Overall, EGFR mutations are present in 40–50% of 
East Asians and 10% of Caucasians.26 However, the 
exact incidence of these mutations in the GCC region 
is unknown; in the current study, it was observed that 
27.9% of patients with adenocarcinomas had EGFR 
mutations in exons 19 or 21. As of late 2010, selected 
NSCLC patients at SQUH are treated with maintenance 
therapy. Compelling data exist suggesting that patients 
with ECOG performance statuses of 0–1 receiving 
maintenance therapy have well-preserved organ 
function and that this form of therapy enhances OS 
by 2–3 months.27–31 Several prognostic and predictive 
markers are also now available to guide oncologists in 
providing customised and individualised evidence-
based care.32 
A major cause of death in the present study 
was either local progression leading to respiratory 
failure, progressive metastasis (i.e. leptomeningeal 
and brain metastases, liver failure, pulmonary 
parenchymal relapse or pleural effusion or both) or 
infections (i.e. pneumonia and sepsis). No deaths were 
attributable to venous thromboembolic phenomena 
or pulmonary embolisms, which may be due to the 
strict thromboprophylaxis policy implemented at 
SQUH. Survival outcomes were very poor for patients 
who were diagnosed NSCLC at a late stage, which 
constituted the vast majority of patients in the studied 
cohort. This incidence of advanced stage NSCLC 
is very similar to that reported by the Surveillance, 
Epidemiology, and End Results (SEER) Program of 
the National Cancer Institute in the USA [Table 4].9 
Advanced NSCLC has a median OS of 10 months.32 
Pemetrexed and targeted agents have been reported to 
enhance survival to 12 months and beyond, while the 
benefits of post-progression bevacizumab are currently 
under investigation.33 In the current study, prolonged 
survival was observed in a few cases treated with 
either TKIs or maintenance therapy; these findings are 
in agreement with those from other studies.34,35
Conclusion
In the current study, the majority of patients with 
NSCLC were found to present at an advanced stage. 
However, survival outcomes were similar to those 
reported by the SEER Program in the USA. To the 
best of the authors’ knowledge, this study is the first 
to describe the trends and outcomes of patients with 
NSCLC in Oman.
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